Megestrol for weight loss in lung cancer patients starting chemotherapy
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new form of megestrol, a medicine that helps stimulate appetite and promote weight gain, in people with advanced non-small cell lung cancer who are starting their first chemotherapy and are at risk of malnutrition. The goal is to see if it improves nutrition and overall well-being during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with non-small cell lung cancer that is advanced (stage IIIB, IIIC, or IV) and cannot be removed with surgery.
- You have not had chemotherapy for advanced lung cancer before, though you may have had it earlier as part of other treatment if it was more than 6 months ago.
- You are at risk of malnutrition, which will be checked with a simple screening tool.
- You are generally able to care for yourself (ECOG score 0-2) and have a life expectancy of at least 6 months.
- Your cancer does not have certain genetic changes (EGFR mutation or ALK rearrangement), and you have at least one tumor that can be measured on scans.
- Your major organs (blood, kidneys, liver, heart) are working well enough, as determined by standard tests.
- You are not currently taking other appetite stimulants or certain other medications that could interfere with the study.
- You do not have conditions that severely affect eating, such as trouble swallowing, severe nausea, or a blockage in your stomach or intestines.
- You have not had certain heart or blood vessel problems in the past year, and you do not have uncontrolled high blood pressure.
- You are willing to use effective birth control if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a medication called megestrol acetate (a type of hormone that can boost appetite and help with weight gain) can improve outcomes for people with advanced non-small cell lung cancer who are malnourished. It is used as part of first-line treatment, meaning before any chemotherapy for the advanced cancer.
This study tests whether a special form of megestrol acetate (a medicine used to help with weight and appetite) can improve outcomes when given alongside standard chemotherapy and radiation for people with stage III non-small cell lung cancer. It is for patients who are not overweight and who are not already using other appetite-boosting medications.
This trial tests a newer form of megestrol acetate (a medication that can help with appetite and weight) given alongside standard chemotherapy and radiation for locally advanced cervical cancer that cannot be removed by surgery. The study aims to see if this combination is safe and effective.
This trial tests a drug called megestrol acetate, which is a type of progesterone that can help increase appetite and reduce weight loss. It is for people with a certain type of lung cancer (small cell lung cancer) that has spread, especially if they are experiencing early signs of weight loss or frailty.
This study tests a medicine called nanocrystalline megestrol acetate to see if it can help improve appetite and promote weight gain in people with advanced non-small cell lung cancer who are losing weight. If you qualify, you would receive this treatment alongside your regular care to help you feel better and maintain your strength.
This study tests whether adding a drug that boosts appetite and weight to standard lung cancer treatment helps people with advanced small cell lung cancer who are experiencing weight loss and poor appetite. It aims to improve quality of life and treatment outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.